Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022

  1. 1. Idiopathic Pulmonary Fibrosis (IPF) Market- Epidemiology Forecast to 2022The report is a pre – order report and available from 16th April 2013.Further research is a prerequisite to shine a light on Idiopathic Pulmonary Fibrosis (IPF) and offertherapeutic hope to these sufferers. With the approval of the initial IPF small molecule pharmaceuticalthis underserved market is set to change, allowing the better study of patients by extending survivaltime, states new analysis by research and consulting firm GlobalData.For the last decade the IPF therapeutic field has been untapped and dominated by the off-label drug N-acetylcysteine provided for symptomatic relief and costly supportive palliative care. However, newresearch suggests that InterMune’s Esbriet (pirfenidone) – the sole therapeutic approved exclusively forthe treatment of IPF – will work to slow the course of disease in IPF patients, if regulatory and financialbarriers can be overcome. This may then allow for a closer epidemiological study of the disease, withpatients able to survive longer periods of examination.Idiopathic Pulmonary Fibrosis (IPF) is a fibrosing, interstitial form of chronic pneumonia, defined byirreversible and variable scarring, stiffening, and thickening of the lung tissues, which ultimately resultsin progressive worsening of pulmonary function. Little is understood about the fatal disease; the firstinternational consensus statement defining the diagnosis, evaluation, and management of IPF patientsonly published in 2000. IPF also has the worst prognosis of any type of idiopathic interstitial pneumonia,with only three to five years of median survival. This poor survival rate, combined with IPF’s lowincidence rate, makes studying the epidemiology of the condition extremely difficult.For complete report, visit @ Samantha Fernando, GlobalData’s Analyst covering Immunology, discusses the difficulties faced inEsbriet launch and availability despite EU approval in 2011:“The sole EU-approved IPF therapeutic, InterMune’s Esbriet has suffered delays in launching andavailability within each EU market, due to complications regarding licensing, pricing, reimbursement andconfidentiality, which has hindered market access to a much sought-after drug.“Esbriet’s high price and minimal therapeutic effect also negatively affected its launch – prices exceed€30,000 [$39,350] per annum per patient, and the drug only slows disease progression, rather thanhalting it completely.”There was renewed hope for IPF sufferers in the UK on March 20, 2013 following the National Institutefor Health and Clinical Excellence (NICE) overturning a previous decision to not recommend Esbriet. Thisdue to InterMune’s provision of a Patient Access Scheme (PAS), details of which remain confidential butare sure to provide improved drug accessibility to patients.Esbriet is also currently undergoing an additional Phase III trial in the US as requested by the FDA, owingto safety concerns regarding suitability of clinical trial endpoints used for this chronic disease. The US
  2. 2. had 31,821 prevalent cases of IPF in 2012, and the nation’s large elderly population will ensure that thislevel of prevalence continues to 2022, making the FDA’s decision on Esbriet significant for the IPFtherapeutics market.GlobalData epidemiologists forecast that there will be 45,718 incident cases of IPF across the US, France,Germany, Italy, Spain, and UK in 2022, with incidence rates and prevalence proportions remainingconstant throughout the next decade (a slight projected increase in the IPF population due only to thegrowing and aging global population). Despite this, the IPF therapeutics market in these countries isprojected to undergo exponential growth over 2012-2017, at a Compound Annual Growth Rate (CAGR)of 87%, creating a fiercely competitive environment.“InterMune is a one-drug company wholly reliant on Esbriet,” states Fernando, “and the company iscurrently filing a lawsuit against the EMA challenging the agency’s decision to disclose documentationon the company’s product, as InterMune will become vulnerable to competing companies ifcommercially confidential information were made accessible. InterMune has also been plagued withacquisition deal speculation, which is anticipated to intensify after Esbriet completes its Phase III FDAtrial in 2014.”The report is a pre – order report and available from 16th April 2013.Contact for more details.